Gene Therapies Market Report- Production Strategies and Challenges in the Manufacture: Glybera

“Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis” discusses all gene therapies, including not only those which involve genetic modification, but also RNAi, CAR-T cell and aptamer-based therapies.

Get a FREE PDF Sample Copy of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1344314

Currently Approved Gene Therapies in this Report-
Glybera (alipogene tiparvovec)
Kynamro (mipomersen)
Macugen (pegaptanib)
Vitravene (fomivirsen)
Gendicine (rAd-p53)
Oncorine (rAd5-H101)
Neovasculgen (Pl-VEGF165)
Exondys 51 (eteplirsen)
Spinraza (nusinersen)
Strimvelis (GSK-2696273)
Kymriah (tisagenlecleucel)
Yescarta (axicabtagene ciloleucel)
Imlygic (talimogene laherparepvec)
Zalmoxis (Allogenic T cells encodng LNGFR and HSV-TK)
Luxturna (voretigene neparvovec)

In 2017 alone, the marketing approvals of Kymriah, Yescarta and Luxturna added to this growing class of products. However, due to various challenges, progress in developing this technology and achieving commercial uptake over the past few decades has been slow.

In the short term, there is a shortfall in global gene and cell therapy manufacturing capacity, and in the long-term the personalized nature of many gene and cell therapies represents a further challenge that will not be met by the currently used, centralized biopharmaceutical manufacturing model.

Additionally, the very small number of patients in orphan genetic diseases that these therapies are especially well suited for has caused commercial difficulties for drugs such as Glybera and Strimvelis, and the high pricing of these therapies in response to the low patient number presented strong reimbursement difficulties.

However, the pipeline for gene therapies is robust; there are 985 in vivo gene therapies, and a further 354 CAR-T cell therapies currently in pipeline development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage.

There are also currently 23 gene therapy programs in Phase III development. This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of Gene Therapy, and assesses key developments in delivery vector technology, and challenges and advances associated with the production of such vectors.

Scope of this Report-
Why do gene therapies still occupy only a minimal market share in their respective indications?
What can be learned from the gene therapies that have already reached the market, especially from products that have faced commercial difficulties, such as Glybera and Strimvelis?
What are the prospects of recent approvals such as Luxturna, Kymriah and Strimvelis?
What are the relative advantages and disadvantages of each vector type and which hold the most promise?
What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?
How will the entry of gene therapies into the market change the global manufacturing landscape?

Reasons to buy this Report-
Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products.
Assess the pipeline for gene therapies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, central nervous system disorders, ophthalmology, and genetic disorders.
Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline.
Understand the level of involvement in the landscape on the part of big pharma companies, and the extent to how gene therapies fit into the overall portfolios of companies in this field.
Understand the strategic consolidations landscape in gene therapies across the past decade.

Discount on this Full Report @ https://www.reportsnreports.com/purchase.aspx?name=1344314

List of Tables in this report-
Table 1: Gene Therapies, Global, Methods of Gene Silencing, 2017 10
Table 2: Gene Therapies, Global, Types of Viral Vector for Gene Therapy Delivery, 2017 15
Table 3: Gene Therapies, Global, Types of Non-Viral Vector for Gene Therapy Delivery, 2017 19
Table 4: Gene Therapies, Global, Clinical Characteristics of Glybera, 2017 23
Table 5: Gene Therapies, Global, Clinical Characteristics of Kynamro, 2017 24
Table 6: Gene Therapies, Global, Clinical Characteristics of Macugen, 2017 25
Table 7: Gene Therapies, Global, Clinical Characteristics of Vitravene, 2017 25
Table 8: Gene Therapies, Global, Clinical Characteristics of Gendicine, 2017 26
Table 9: Gene Therapies, Global, Clinical Characteristics of Oncorine, 2017 27
Table 10: Gene Therapies, Global, Clinical Characteristics of Neovasculgen, 2017 27
Table 11: Gene Therapies, Global, Clinical Characteristics of Exondys 51, 2017 29
Table 12: Gene Therapies, Global, Clinical Characteristics of Spinraza, 2017 30
Table 13: Gene Therapies, Global, Clinical Characteristics of Strimvelis, 2017 32
Table 14: Gene Therapies, Global, Clinical Characteristics of Kymriah, 2017 33
Table 15: Gene Therapies, Global, Clinical Characteristics of Yescarta, 2017 34
Table 16: Gene Therapies, Global, Clinical Characteristics of Imlygic, 2017 35
Table 17: Gene Therapies, Global, Clinical Characteristics of Zalmoxis, 2017 36
Table 18: Gene Therapies, Global, Clinical Characteristics of Luxturna, 2017 37
Table 19: Gene Therapies, Global, Impurities in the AAV Production Process, 2017 41
Table 20: Gene Therapies, Global, Overall Challenges to Gene Therapy Development, 2017 44
Table 21: Gene Therapies, Global, Comparison of CRISPR-Cas9, ZFNs and TALENs as Gene Editing Platforms, 2017 57
and more...

ReportsnReports.com
+ 1 888 391 5441
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.